K + channel principal subunits are by far the largest and most diverse of the ion channels. This
diversity originates partly from the large number of genes coding for K + channel principal …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide…

Obesity is now reaching epidemic proportions in both developed and developing countries
and is affecting not only adults but also children and adolescents. Over the last 20 years, …

Atherosclerotic disease remains the leading cause of death in industrialized nations despite
major advances in its diagnosis, treatment, and prevention. The increasing epidemic of …

… David Lau reports receiving grants and research support from AstraZeneca, Novo
Nordisk and the Canadian Institutes of Health Research (CIHR); speaker bureau fees from …

Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …

Objective To summarise the long term efficacy of anti-obesity drugs in reducing weight and
improving health status. Design Updated meta-analysis of randomised trials. Data sources …

Many developments have occurred since the publication of the widely-used 2009 Canadian
Cardiovascular Society (CCS) Dyslipidemia guidelines. Here, we present an updated …

… Jacques Genest MD1, Ruth McPherson MD PhD2, Jiri Frohlich MD3, Todd Anderson
MD4, Norm Campbell MD4, André Carpentier MD5, Patrick Couture MD6, Robert Dufour …

Since the publication of the 2012 guidelines new literature has emerged to inform decision-making.
The 2016 guidelines primary panel selected a number of clinically relevant …